Creso Pharma commences sales of cannaQIX® 50 Medicinal Cannabis in Australia
Creso Pharma Limited (ASX:CPH | FRA:1X8) has commenced sales of its flagship medicinal cannabis product cannaQIX® 50 to Burleigh Heads Cannabis, one of Australia’s leading medicinal cannabis distribution companies.
Burleigh Heads Cannabis has confirmed prescriptions are already taking place and the product is receiving very positive feedback from physicians and patients.
Creso Pharma and Burleigh Heads Cannabis have placed initial focus on introducing cannaQIX® 50, which is now being sold in Australia as a therapeutic product via approved channels as ‘LozaCan’.
cannaQIX® 50/LozaCan has been developed to Good Manufacturing Practice (GMP) standards and is produced in Switzerland by Creso Pharma’s partner, Switzerland-based food and pharma development company Domaco, Dr. med Aufdermaur AG to the highest Swiss quality with a ‘Swiss Made’ label.
Creso Pharma and Burleigh Heads Cannabis are exploring the potential to expand their collaboration to include additional therapeutic/medicinal cannabis products from Creso Pharma’s pipeline.
Fast working treatment for chronic pain
cannaQIX 50® is Creso Pharma’s proprietary buccally formulated cannabidiol (CBD) lozenge which is designed to support the management of chronic pain.
Each cannaQIX 50® lozenge contains 50mg of CBD from full spectrum hemp plant extracts along with niacin, vitamins B6, B12, C, and zinc in a standardised pharma-grade formulation produced in Switzerland.
cannaQIX 50® comes in packs of 30 lozenges in a proprietary delivery formulation designed for buccal absorption and to dissolve in the mouth.
This method works faster and more efficiently than tablets or capsules which need to be swallowed and have a high percentage of their ingredients broken down when absorbed through the intestine and passed first through the liver.
By being dissolved in the mouth, the active ingredients enter the bloodstream directly, avoiding this first pass through the liver. cannaQIX 50® lozenges taste great and are a patient-friendly way to administer precise doses of CBD when compared to oil-based alternatives.
Extension of exclusive distribution agreement
The delivery follows the recent signing of an exclusive Distribution Agreement with Burleigh Heads Cannabis in April, and the securing of an import permit for Australia.
The collaboration will enable Creso Pharma to leverage Burleigh Heads Cannabis and CDA’s local regulatory experience and established distribution networks to facilitate patient access to its products in Australia.
Burleigh Heads Cannabis is a subsidiary of CDA Health Pty Ltd, an established Australian business supporting patient access to medical cannabis products in Australia.
Through its affordable CDA-branded products and CDA Clinics, the group assists doctors and patients in navigating the process of applying, prescribing and sourcing medical cannabis legally, while also providing educational resources and one-to-one services from their consultant doctors through physical and telehealth clinics.
CDA has completed over 5000 successful Therapeutic Goods Administration (TGA) patient approvals since launching in October 2018.
Discussing this milestone event and pointing to its significance in terms of new product launches, Dr Miri Halperin Wernli, Creso Pharma’s chief executive and co-founder said, “We are pleased to announce the first delivery of cannaQIX® 50 in Australia.
‘’Burleigh Heads Cannabis and CDA Clinics Australia continue to rapidly expand their patient reach with their extensive distribution network.
‘’This close partnership enables us to fulfil our mission of bringing life-improving products to patients in Australia.
‘’We’re delighted to announce this progress and look forward to further new product introductions in the near future.”
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.